Table 2.
Patient Cohort Used for Quantitative PCR Experiments (Validation Cohort)
| Age—mean (min, max) | 58 (42–79) | (years) |
| Gender—no. (%) | ||
| Female | 5 | (33) |
| Male | 15 | (66) |
| Ancestry region—no. | ||
| Europe | 18 | (90) |
| Asia | 1 | (5) |
| Africa | 1 | (5) |
| Underlying liver cirrhosis | 20 | (100) |
| ISHAK fibrosis score = 6 | 20 | (100) |
| METAVIR fibrosis score = F4 | 20 | (100) |
| Cause of liver cirrhosis—no. (%) | ||
| HCV | 20 | (100) |
| HCV genotype—no. (%) | ||
| Genotype 1 | 11 | (55) |
| Genotype 2 | 1 | (5) |
| Genotype 3 | 2 | (10) |
| Unknown | 6 | (30) |
| Child-Pugh class—no. (%)⁎ | ||
| A | 16 | (80) |
| B | 3 | (15) |
| C | 1 | (5) |
| MELD score—median (min, max)⁎ | 11.6 (6, 29) | |
| AFP serum level—median (min, max)⁎ | 15 (1.9, 84,798) | ng/ml |
| BCLC stage—no. (%)⁎ | ||
| 0 | 8 | (40) |
| A | 11 | (55) |
| B | 1 | (5) |
| Histologic grading (G)—no. (%)⁎ | ||
| G1 | 3 | (15) |
| G2 | 13 | (65) |
| G3 | 3 | (15) |
| G4 | 1 | (5) |
| Therapy type—no. (%) | ||
| Surgical resection | 11 | (55) |
| Liver transplantation | 9 | (45) |
| TACE prior to resection or transplantation—no. (%) | 12 | (60) |
⁎
At the time point of HCC resection. MELD, Model for End-Stage Liver Disease.